Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160(MN) (ALVAC-HIV): A double-blind controlled randomized study of safety and immunogenicity

被引：0
|
作者：
Tubiana, R
Gomard, E
Fleury, H
Gougeon, ML
Mouthon, B
Picolet, H
Katlama, C
机构：
[1] HOP COCHIN,INSERM,U445,F-75674 PARIS,FRANCE
[2] VIROL LAB,BORDEAUX,FRANCE
[3] PASTEUR MERIEUX SERUMS & VACCINS,LYON,FRANCE
[4] INST PASTEUR,PARIS,FRANCE
来源：
AIDS | 1997年 / 11卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：819 / 820
页数：2
相关论文
共 50 条
  • [1] CYTOTOXIC T-LYMPHOCYTE RESPONSES TO RECOMBINANT CANARYPOX-GP160 MN (ALVAC VCP125, HIV-1 GP160 MN) IN HIV-1 UNINFECTED ADULT VOLUNTEERS
    EGAN, MA
    WEINHOLD, K
    PAOLETTI, E
    TARTAGLIA, J
    CLEMENTS, ML
    PAVLAT, W
    SILICIANO, RF
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 : S89 - S89
  • [2] Therapeutic immunisation with recombinant gp160 in HIV-1 infection:: a randomised double-blind placebo-controlled trial
    Sandström, E
    Wahren, B
    LANCET, 1999, 353 (9166): : 1735 - 1742
  • [3] Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type I (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp160 of HIV-1 and boosted with a recombinant gp160
    Fleury, B
    Janvier, G
    Pialoux, G
    Buseyne, F
    Robertson, MN
    Tartaglia, J
    Paoletti, E
    Kieny, MP
    Excler, JL
    Riviere, Y
    JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (04): : 734 - 738
  • [4] THE SAFETY AND IMMUNOGENICITY OF A HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) RECOMBINANT GP160 CANDIDATE VACCINE IN HUMANS
    DOLIN, R
    GRAHAM, BS
    GREENBERG, SB
    TACKET, CO
    BELSHE, RB
    MIDTHUN, K
    CLEMENTS, ML
    GORSE, GJ
    HORGAN, BW
    ATMAR, RL
    KARZON, DT
    BONNEZ, W
    FERNIE, BF
    MONTEFIORI, DC
    STABLEIN, DM
    SMITH, GE
    KOFF, WC
    ANNALS OF INTERNAL MEDICINE, 1991, 114 (02) : 119 - 127
  • [5] Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial
    Goebel, FD
    Mannhalter, JW
    Belshe, RB
    Eibl, MM
    Grob, PJ
    de Gruttolae, V
    Griffiths, PD
    Erfle, V
    Kunschak, M
    Engl, W
    AIDS, 1999, 13 (12) : 1461 - 1468
  • [6] SAFETY AND IMMUNOGENICITY OF LAMBDA-BACULOVIRUS DERIVED HIV-1 IIIB RECOMBINANT GP160 VACCINE (VAXSYN(R)) IN HUMANS
    KEEFER, M
    BELSHE, R
    CLEMENTS, M
    GRAHAM, B
    COREY, L
    BOLOGNESI, D
    STABLEIN, D
    FAST, P
    MONTEFIORI, D
    SMITH, G
    DOLIN, R
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1993, 9 : S113 - S113
  • [7] Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160
    Lee, D
    Graham, BS
    Chiu, YL
    Gilbert, PB
    McElrath, MJ
    Belshe, RB
    Buchbinder, SP
    Sheppard, HW
    Koblin, BA
    Mayer, KH
    Keefer, MC
    Mulligan, MJ
    Celum, CL
    JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (05): : 903 - 907
  • [8] Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gp160 vaccine among adults with advanced HIV infection
    DeMaria, A
    Kunches, L
    Mayer, K
    Cohen, C
    Epstein, P
    Werner, B
    Day, J
    DeCristofaro, J
    Landers, S
    Tang, Y
    Coady, W
    JOURNAL OF HUMAN VIROLOGY, 2000, 3 (04) : 182 - 192
  • [9] Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene
    RJ O'Connell
    VR Polonis
    S Ratto-Kim
    J Cox
    LL Jagodzinski
    J Malia
    NL Michael
    J Excler
    ML Robb
    JH Kim
    Retrovirology, 9
  • [10] Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene
    O'Connell, R. J.
    Polonis, V. R.
    Ratto-Kim, S.
    Cox, J.
    Jagodzinski, L. L.
    Malia, J.
    Michael, N. L.
    Excler, J.
    Robb, M. L.
    Kim, J. H.
    RETROVIROLOGY, 2012, 9
12345